Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) gapped up before the market opened on Thursday after Deutsche Bank Aktiengesellschaft raised their price target on the stock from $40.00 to ...
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...
Analysts have set 12-month price targets for Alkermes, revealing an average target of $42.0, a high estimate of $52.00, and a ...
Thrivent Financial for Lutherans reduced its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 3.3% in the fourth ...
Mural Oncology (NASDAQ:MURA) stock plummets 47% as the company, a spinoff of Alkermes (ALKS) halts a Phase 3 trial for its ...
OptiNose, Inc. (NASDAQ:OPTN) faces a pessimistic outlook from investment analysts with a target price significantly lower than its market price. Collegium Pharmaceutical, Inc. (COLL) is perceived as ...
In a report released today, Jason Gerberry from Bank of America Securities maintained a Hold rating on Alkermes (ALKS – Research Report), with ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vicarious Surgical (RBOT – Research Report), Alkermes (ALKS ...
Investor's Business Daily on MSN11d
Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy PointsOn St. Patrick's Day, everybody's a little Irish. Alkermes, Aon, Jazz Pharmaceuticals, PDD Holdings and CRH are five ...
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback